High-Dose 90Y Mx-Diethylenetriaminepentaacetic Acid (DTPA)-BrE-3 and Autologous Hematopoietic Stem Cell Support (AHSCS) for the Treatment of Advanced Breast Cancer: A Phase I Trial

摘要: Abstract This Phase I trial explores the use of high-dose 90 Y conjugated to antibreast cancer monoclonal antibody BrE-3 and autologous hematologic cell support in treatment women with stage four breast cancer. Nine heavily pretreated disease were enrolled. All patients had BrE-3-positive tumors by immunostaining treated increasing doses (15 mCi/m 2 , 3 patients), 20 mCi/M (six a fixed (50 mg) dose BrE-3. 111 In-labeled (5 mCi) was given simultaneously for scanning purposes. The only toxicity noted hematological. Grade 4 platelet requiring transfusion occurred patients. WBC seen two that resolved 3–9 days. hematological nadirs approximately 25 days after treatment. Objective partial responses 8 (50%) measurable tumors. Dose escalation is ongoing.